Overview

CV Events in Emetogenic Chemotherapy

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Emetics